What is the most common variant of Hodgkin's Lymphoma (HL) in India?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Most Common Hodgkin's Lymphoma Variant in India

Mixed cellularity is the most common histological subtype of Hodgkin's lymphoma in India, accounting for approximately 50-55% of all cases. 1, 2

Epidemiological Profile of Hodgkin's Lymphoma in India

The epidemiological profile of Hodgkin's lymphoma (HL) in India differs significantly from Western countries in several key aspects:

  • Histological distribution:

    • Mixed cellularity: 45.8-54% of cases 1, 2
    • Lymphocyte depleted: Together with mixed cellularity forms 68% of all HL cases 1
    • Nodular sclerosis: Only 9% of cases in India 1, compared to being the predominant subtype in Western countries
  • Age distribution:

    • Bimodal age pattern with peak in the second decade of life 1
    • Median age of onset around 28 years 2
    • Higher incidence in childhood compared to Western countries 1
  • Gender distribution:

    • Strong male predominance with male-to-female ratio of 3.8:1 2

Comparison with Western Patterns

In Western countries, the pattern of Hodgkin's lymphoma differs considerably:

  • Nodular sclerosis is the predominant subtype in Western populations 3, 4
  • Bimodal age distribution with first peak in third decade and second peak after age 55 5, 6
  • Incidence of 2-3/100,000 per year 5

Clinical Presentation in Indian Population

The clinical presentation of Hodgkin's lymphoma in Indian patients typically includes:

  • Neck swelling as the most common symptom (58.3%) 2
  • Peripheral lymphadenopathy as the most common sign (83.3%) 2
  • Cervical lymph node involvement in 79.2% of cases 2
  • Advanced disease at presentation (54.2% in Stage III/IV) 2
  • Bone marrow involvement in 8.33% of cases 2

Significance for Clinical Practice

The predominance of mixed cellularity subtype in India has important clinical implications:

  • Mixed cellularity is generally associated with more advanced disease at presentation 7
  • This subtype often requires more aggressive treatment approaches
  • Understanding this epidemiological pattern helps in developing appropriate regional treatment protocols

Historical Perspective

A comprehensive review of 1082 cases of Hodgkin's disease recorded at the Tata Memorial Hospital in Bombay over 35 years confirmed that mixed cellularity was consistently the most frequent histological subtype in India 1. This pattern aligns with what Correa and O'Connor described as the "type-I pattern" of Hodgkin's disease, which appears to be characteristic of developing countries 1.

The distinct clinicopathologic profile of Hodgkin's lymphoma in India emphasizes the importance of understanding regional variations in disease presentation for appropriate diagnosis and management, particularly in rural communities with limited access to sophisticated medical services 2.

References

Research

Hodgkin lymphoma.

Critical reviews in oncology/hematology, 2013

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Hodgkin Lymphoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.